Different ALK inhibitors Lead to Different Outcomes in ALK-Positive Non-Small Cell Lung Cancer
Dr. Joshua Sabari, a professor at New York University's Department of Medicine, has recently spoken about the different treatment options for ALK-positive non-small cell lung cancer (NSCLC). Specifically, he discussed…